ArticleEuropean radiology2021
Standardizing percutaneous Microwave Ablation in the treatment of Lung Tumors: a prospective multicenter trial (MALT study).
Article in European radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Dielectric properties, thermal properties, blood perfusion rate: which biophysical parameter is the leading source of variability of microwave ablation models in lung?International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026Article
- Pulmonary nodules: classification, biomarkers, signaling pathways, diseases, early diagnosis and management.Signal transduction and targeted therapy · 2026Review
- Thermal ablation of lung metastases in children: what every paediatric radiologist should know.Pediatric radiology · 2026Review
- Advances in Percutaneous and Endovascular Locoregional Therapies for Primary and Metastatic Lung Cancer.Cancers · 2026Review
- Review
- Performance of an Anti-Phase Technology-Powered Microwave Ablation System on Ex Vivo Liver, Lung and Kidney: Analysis of Temperature Trend, Ablation Size and Sphericity.Cardiovascular and interventional radiology · 2024Article
- The combined application of electromagnetic navigation and porcine fibrin sealant in microwave ablation of lung tumors.Heliyon · 2024Article
- Enhanced abscopal anti-tumor response via a triple combination of thermal ablation, IL-21, and PD-1 inhibition therapy.Cancer immunology, immunotherapy : CII · 2024Article
- Risk prediction of intraoperative pain in percutaneous microwave ablation of lung tumors under CT guidance.European radiology · 2023Article
- Microwave ablation via a flexible catheter for the treatment of nonsurgical peripheral lung cancer: A pilot study.Thoracic cancer · 2022Article
- A prospective trial of CT-guided percutaneous microwave ablation for lung tumors.Journal of thoracic disease · 2022Article
- Augmented fluoroscopy guided transbronchial pulmonary microwave ablation using a steerable sheath.Translational lung cancer research · 2022Article
- Survival benefit of thermal ablation therapy for patients with stage II-III non-small cell lung cancer: A propensity-matched analysis.Frontiers in oncology · 2022Article
- Image-guided percutaneous ablation for lung malignancies.Frontiers in oncology · 2022Review
- Immunogenic change after percutaneous microwave ablation in pulmonary malignancies: Variation in immune cell subsets and cytokines in peripheral blood.Frontiers in immunology · 2022Article
- Cryoablation in Locoregional Management of Complex Unresectable Chest Neoplasms.Tomography (Ann Arbor, Mich.) · 2021Article
- Thermal Ablation for Papillary Thyroid Microcarcinoma: How Far We Have Come?Cancer management and research · 2020Review
- Ablation techniques in non-small cell lung cancer patients: experience of a single center.HippokratiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo prospectively assess reproducibility, safety, and efficacy of microwave ablation (MWA) in the treatment of unresectable primary and secondary pulmonary tumors.
methodsPatients with unresectable primary and metastatic lung tumors up to 4 cm were enrolled in a multicenter prospective clinical trial and underwent CT-guided MWA. Treatments were delivered using pre-defined MW power and duration settings, based on target tumor size and histology classifications. Patients were followed for up to 24 months. Treatment safety, efficacy, and reproducibility were assessed. Ablation volumes were measured at CT scan and compared with ablation volumes obtained on ex vivo bovine liver using equal treatment settings.
resultsFrom September 2015 to September 2017, 69 MWAs were performed in 54 patients, achieving technical success in all cases and treatment completion without deviations from the standardized protocol in 61 procedures (88.4%). Immediate post-MWA CT scans showed ablation dimensions smaller by about 25% than in the ex vivo model; however, a remarkable volumetric increase (40%) of the treated area was observed at 1 month post-ablation. No treatment-related deaths nor complications were recorded. Treatments of equal power and duration yielded fairly reproducible ablation dimensions at 48-h post-MWA scans. In comparison with the ex vivo liver model, in vivo ablation sizes were systematically smaller, by about 25%. Overall LPR was 24.7%, with an average TLP of 8.1 months. OS rates at 12 and 24 months were 98.0% and 71.3%, respectively.
conclusionsPercutaneous CT-guided MWA is a reproducible, safe, and effective treatment for malignant lung tumors up to 4 cm in size. KEY POINTS: • Percutaneous MWA treatment of primary and secondary lung tumors is a repeatable, safe, and effective therapeutic option. • It provides a fairly reproducible performance on both the long and short axis of the ablation zone. • When using pre-defined treatment duration and power settings according to tumor histology and size, LPR does not increase with increasing tumor size (up to 4 cm) for both primary and metastatic tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.